IMPRES - Improving Memory after RRSO
Quality of Life:
Breast Cancer Survivor
High Risk But No Cancer
Ovarian Cancer Survivor
Study Contact Information
The study is being conducted by researchers at the University of Pennsylvania. Contact Brianna Soreth, Research Coordinator by phone at (215) 573-9695 or by email.
About the Study
Dr. C. Neill Epperson and her research team at the Penn Center for Women's Behavioral Wellness are studying the effects of a stimulant medication called Vyvanse® on memory and attention in women who had surgery to remove their ovaries to lower their risk for ovarian cancer (risk-reducing salpingo-oophorectomy or RRSO).
Read our blog that includes an interview with a study participant.
NOTE: The study offers travel reimbursements and hotel accommodations for those eligible to participate.
Type of Study
This is a 2-arm, double-blind, randomized, placebo controled, cross-over study.
- This is a randomized study, meaning that participants will be placed into one of the two treatment groups by chance. Neither patients nor the research doctor will choose the group participants are placed in.
- This is a double-blind study, neither the patient in the study nor their doctor will know which group they have been assigned to.
- The study has two arms. This means that patients in the study are placed in one of two different groups. One group will received the drug Vyvanse® and the other group will receive a placebo. After 6 weeks of treatment, patients will cross over to the other arm of the study.
- This is a crossover study. This means that in the second half of the study, patients who began in the placebo arm will be placed on the drug Vyvanse®, and patients who began on Vyvanse® will be placed on a placebo.
What the Study Entails
Participants who meet initial criteria and enroll will follow this schedule:
- Screening visit in-office at the University of Pennsylvania or remotely (via Skype).
- Baseline (pre-treatment) brain MRI.
- Randomized to one of two arms. One group will receive Vyvanse for six weeks and the other group will receive a placebo for six weeks.
- After a 6-week course of treatment, participants will undergo a second brain MRI.
- After a 2 week period of no study medication, participants will cross over to the other arm of the study. Women who received six weeks of placebo will receive Vyvanse®. Women who received Vyvanse® will switch to receiving a placebo.
- Upon finishing the second 6-week course of treatment, participants will undergo a third (and final) brain scan.
Participants will be compensated for their time participating in the study. Total compensation is up to $650.
Four out of seven visits can be completed remotely. The remaining three visits are MRI sessions that must be completed at the University of Pennsylvania.
Study Lead Investigator
Neill Epperson, MD: firstname.lastname@example.org
Susan Domchek, MD.
- Philadelphia, PA: University of Pennsylvania
- Contact Brianna Soreth, Research Coordinator by phone at (215) 573-9695 or by email.